Amitesh Verma,Sarwish Rafiq
Amitesh Verma
Genetic modification of T cells to express chimeric antigen receptors (CARs) has yielded remarkable clinical outcomes and initiated a novel era for cancer immunotherapy. The impressive clinical responses seen in hematologic malignancies hav...
Allogeneic Tumor Antigen-Specific T Cells for Broadly Applicable Adoptive Cell Therapy of Cancer [0.03%]
具有同种异体肿瘤抗原特异性的T细胞用于癌症的广泛适用性过继性细胞疗法
Zaki Molvi,Richard J O&#x;Reilly
Zaki Molvi
T cells specific for major histocompatibility complex (MHC)-presented tumor antigens are capable of inducing durable remissions when adoptively transferred to patients with refractory cancers presenting such antigens. When such T cells are ...
Engaging Pattern Recognition Receptors in Solid Tumors to Generate Systemic Antitumor Immunity [0.03%]
激活实体肿瘤中的模式识别受体以产生全身性抗肿瘤免疫反应
Michael Brown
Michael Brown
Malignant tumors frequently exploit innate immunity to evade immune surveillance. The priming, function, and polarization of antitumor immunity fundamentally depends upon context provided by the innate immune system, particularly antigen pr...
Vishal Navani,Moira C Graves,Hiren Mandaliya et al.
Vishal Navani et al.
Melanoma gave science a window into the role immune evasion plays in the development of malignancy. The entire spectrum of immune focused anti-cancer therapies has been subjected to clinical trials in this disease, with limited success unti...
Diana C DeLucia,John K Lee
Diana C DeLucia
Cancer immunotherapy, or the utilization of components of the immune system to target and eliminate cancer, has become a highly active area of research in the past several decades and a common treatment strategy for several cancer types. Th...
Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Acute Lymphoblastic Leukemia (B-ALL) [0.03%]
嵌合抗原受体(CAR)T细胞治疗B细胞性急性淋巴性白血病(B-ALL)
Geoffrey Shouse,Elizabeth Budde,Stephen Forman
Geoffrey Shouse
With the exploitation of adoptive immunotherapies, the outcomes of patients with relapsed and refractory B cell hematologic malignancies have seen drastic improvements. To this end, a paradigm shift away from toxic and ineffective chemother...
Sheeja T Pullarkat,Winnie Wu,Vinod Pullarkat
Sheeja T Pullarkat
Mastocytosis is a rare hematologic disorder characterized by abnormal proliferation and accumulation of neoplastic mast cells in various body sites. Isolated skin involvement is termed cutaneous mastocytosis (CM) and the term systemic masto...
Haris Ali,Vinod Pullarkat,David Snyder
Haris Ali
The classical myeloproliferative neoplasms (MPN) are characterized by clonal expansion of one or more hematopoietic cell lineages and are driven by mutations that activate constitutive signaling via JAK2 pathway. The criteria for diagnosis ...
Tanya Siddiqi
Tanya Siddiqi
Chronic lymphocytic leukemia (CLL), the most common leukemia in the western world, is characterized by the accumulation of monoclonal B-lymphocytes in the bone marrow and lymphoid organs. Signaling via the B-cell receptor and Bruton tyrosin...
Current Management and New Developments in the Treatment of Myelodysplastic Syndrome [0.03%]
骨髓增生异常综合征的治疗现状及进展
Shukaib Arslan,Samer Khaled,Ryotaro Nakamura
Shukaib Arslan
Myelodysplastic syndrome (MDS) is a heterogeneous hematological neoplasm with a wide range of clinical presentations from isolated anemia to pancytopenia and propensity to transform to acute myeloid leukemia. MDS is characterized by morphol...